Evaluated for Gaucher disease.

‘This is the first time a substance targeting Gaucher disease has been tested in a mouse style of Parkinson's disease and was shown to be effective,’ said the study's senior author, Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology at UCLA and director of the UCLA Center for the analysis of Parkinson's Disease. ‘The promising results in this study suggest that further investigation of this compound in Parkinson's disease is warranted.’ Related StoriesUnderstanding how schizophrenia impacts workings of the brainBerkeley Laboratory scientists identify genetic elements that impact neurological disorders and body weightProtein sensor for proprioception foundIn the study, the researchers used mice that were engineered to make too much alpha-synuclein which genetically, over time, led the pets to develop deficits very similar to those observed in humans with Parkinson's.AIDS, health groups submit remarks to FDA prior to agency’s review of PrEP In public remarks [.pdf] submitted this week, a group of 14 leading HIV/Helps and health agencies stated their support for Food and Drug Administration approval of emtricitabine/tenofovir disoproxil fumarate [TDF/FTC]. As pre-exposure prophylaxis to prevent HIV disease in adult women and men, a press release from AVAC: Global Advocacy for HIV Prevention says. Modeling studies show that widespread usage of PrEP could reduce brand-new HIV infections, and the scale of the global HIV epidemic thus, substantially around the world, the press release says, adding, The FDA’s decision on TDF/FTC as PrEP may help pave the way for global health funders and developing countries to intensify their planning for execution .